It is very uncertain whether single‐dose changes persistent bacteriuria compared with short‐course (3‐7 days) antibiotics (very low certainty).
It is very uncertain whether single‐dose changes recurrence compared with short‐course (3‐7 days) antibiotics (very low certainty).
It is very uncertain whether single‐dose changes re‐infection compared with short‐course (3‐7 days) antibiotics (very low certainty).
It is very uncertain whether single‐dose changes persistent bacteriuria compared with conventional 10‐day antibiotic treatment (very low certainty).
It is very uncertain whether single‐dose changes persistent symptoms compared with conventional 10‐day antibiotic treatment (very low certainty).
It is very uncertain whether single‐dose changes persistent bacteriuria and symptoms compared with conventional 10‐day antibiotic treatment (very low certainty).
It is very uncertain whether single‐dose changes recurrence compared with conventional 10‐day antibiotic treatment (very low certainty).
It is very uncertain whether single‐dose fosfomycin changes persistent bacteriuria compared with single‐dose netilmicin (very low certainty).
It is very uncertain whether single‐dose fosfomycin changes recurrence compared with single‐dose netilmicin (very low certainty).
Single‐dose, preoperative MMC‐EMDA probably leads to lower time to recurrence compared with single‐dose, postoperative MMC‐PD (moderate certainty).
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes time to progression compared with single‐dose, postoperative MMC‐PD (very low certainty).
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with single‐dose, postoperative MMC‐PD (very low certainty).
Single‐dose, preoperative MMC‐EMDA showed no clear difference in disease‐specific survival compared with single‐dose, postoperative MMC‐PD (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether single‐dose antibiotic changes no cure ‐ all trials compared with short‐course (four‐ to seven‐day) antibiotic (very low certainty).
It is very uncertain whether single‐dose antibiotic changes recurrent asymptomatic bacteriuria ‐ all trials compared with short‐course (four‐ to seven‐day) antibiotic (very low certainty).
It is very uncertain whether single‐dose antibiotic changes pyelonephritis ‐ Same antimicrobial agent only4 compared with short‐course (four‐ to seven‐day) antibiotic (very low certainty).
Single‐dose antibiotic leads to higher low birthweight ‐ Same antimicrobial agent only compared with short‐course (four‐ to seven‐day) antibiotic (high certainty).
Single‐dose antibiotic showed no clear difference in preterm delivery ‐ Same antimicrobial agent only compared with short‐course (four‐ to seven‐day) antibiotic (moderate certainty).
Single‐dose antibiotic may leads to lower side effects ‐ all trials compared with short‐course (four‐ to seven‐day) antibiotic (low certainty).